The systematic characterization of the tumor of the CNS identified HER2, HER3, NECTIN4, TROP2, CLDN6, CLDN18.2, and CD276/B7H3 proteins as potential therapeutic targets (Figures 3, 4). This evidence concerns the gene CD276 and neoplasm.